AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6373094
Drug: Cephalexin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 1.0 g or 0.5 g daily on a qid regimen (29 mg/kg mean daily dose)
Trial: 29125702
Drug: PTL101 containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTL101 containing 10 mg CBD
Trial: 29125702
Drug: PTL101 containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTL101 containing 100 mg CBD
Trial: 29125702
Drug: Sativex oromucosal
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex oromucosal spray (reference product)
Trial: 1596595
Drug: Other classes
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other classes of drugs (vasodilators, antiplatelet drugs, anticoagulants, prostaglandins)
Trial: 22541408
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (200 μg/d)
Trial: 18251036
Drug: Long-term CS-based
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term CS-based regimen with no antibody induction (control group; n = 16)
Trial: 15511603
Drug: Low-dose 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose 0.25 mg dexamethasone suppression test (LD-DST)
Trial: 10630494
Drug: Clarithromycin (CLA)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CLA) 250 mg
Trial: 1934204
Drug: Indomethacin suppositories,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories, 100 mg q8hr for five doses
Trial: 6130197
Drug: Cl2MDP 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cl2MDP 1600 mg/day orally
Trial: 26946419
Drug: Ologen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ologen implant (OLO)
Trial: 16240703
Drug: Bimosiamose disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimosiamose disodium 30 mg/kg
Trial: 12091327
Drug: Lamivudine prophylaxis
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine prophylaxis administered to 13 patients for 1 to 60 days (mean, 15 days) before immunosuppressive treatment and continued for 0.5 to 24 months (mean, 7 months) after initiation of immunosuppression.
Trial: 10337288
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide gel used nightly for 2 weeks
Trial: 9005783
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Ofloxacin
Trial: 2003657
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg labetalol
Trial: 2003657
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg labetalol
Trial: 30328648
Drug: Zolpidem (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (0.25 mg/kg)
Trial: 25704750
Drug: ASP015K (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP015K (10, 25, 60, 100 mg twice daily; 50 mg once daily)
Trial: 20650784
Drug: Tested preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tested preparation (orally disintegrating tablets of pentoxyverine citrate)
Trial: 20650784
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (orally disintegrating tablets of pentoxyverine citrate)
Trial: 12762636
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 3 capsules (570 mg of iodine)
Trial: 12762636
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 1 ml of Lipiodol UF (480 mg of iodine)
Trial: 12762636
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of Lipiodol
Trial: 12762636
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Lipiodol
Trial: 10391813
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG vaccination
Trial: 6128313
Drug: Medazepam 10
RxNorm normalized name: medazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medazepam 10 mg
Trial: 27027671
Drug: Palliation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliation of symptoms with oxygen and morphine
Trial: 27027671
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to wishes
Trial: 18500678
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pioglitazone over nine days
Trial: 15598942
Drug: UFT 400
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 400 mg/m² for 1 year after surgery
Trial: 9475816
Drug: Regular team
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular team interventions involving a pharmacist, physician, nurses, undernurses, and nurse's aides discussing drug therapy.
Trial: 8584609
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg NNC 01-0687
Trial: 8584609
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg NNC 01-0687 administered t.i.d. for 14 days
Trial: 2223339
Drug: lignocaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 1.5 mg kg‐1 i.v. 1 min before laryngoscopy
Trial: 2223339
Drug: lignocaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 1.5 mg kg‐1 i.v. 2 min before laryngoscopy
Trial: 2223339
Drug: lignocaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 1.5 mg kg‐1 i.v. 3 min before laryngoscopy
Trial: 372525
Drug: Aspirin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.6 gm/day)
Trial: 24088361
Drug: SR-IFN-α (9,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR-IFN-α (9, 18, 27, and 36 MIU subcutaneous doses)
Trial: 21850272
Drug: Intranasal GHRH
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GHRH (600 µg)
Trial: 11157327
Drug: 1046 kJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1046 kJ energy load supplement
Trial: 11157327
Drug: 2092 kJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2092 kJ energy load supplement
Trial: 11157327
Drug: Fat-rich supplement
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-rich supplement (1046 kJ)
Trial: 11157327
Drug: Carbohydrate-rich supplement
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich supplement (1046 kJ)
Trial: 8092581
Drug: Cryoanesthesia using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoanesthesia using freon spray for venepuncture
Trial: 2663609
Drug: Glucagon and
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon and insulin infusion (1 mg glucagon and 10 units insulin twice daily for one week)
Trial: 22216499
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg theophylline orally
Trial: 23661283
Drug: Trazodone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (25 mg)
Trial: 21740564
Drug: Neutral writing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral writing condition (writing about facts regarding heart disease and its treatment)
Trial: 7634784
Drug: Potent topical
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent topical corticosteroid (betamethasone‐17‐valerate) applied 2x daily for 7 days
Trial: 7634784
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied 2x daily for 7 days
Trial: 6539997
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cyclophosphamide 1 Gm/M2 each month for six months; cis-platinum 100 mg/M2 each month for four months; combination chemotherapy (CISCA) for one patient)
Trial: 18564001
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg/dose every 8 hours for 15 days)
Trial: 7032273
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms trivalent chromium in 5 ml water (Cr)
Trial: 7032273
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml plain water (W)
Trial: 24196948
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) with valproic acid
Trial: 19772514
Drug: Regular nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular nebulized glucocorticoid (400 microg beclomethasone bid) plus prn bronchodilator (2500 microg salbutamol)
Trial: 19772514
Drug: prn nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prn nebulized bronchodilator/glucocorticoid combination (800 microg beclomethasone/1600 microg salbutamol)
Trial: 10052021
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of vitamin C (C)
Trial: 7734260
Drug: Neostigmine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.04 mg kg‐1
Trial: 7734260
Drug: Pyridostigmine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 0.3 mg kg‐1
Trial: 7734260
Drug: Edrophonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.25 mg kg‐1 with Pyridostigmine 0.15 mg kg‐1
Trial: 6174864
Drug: Higher-dose Human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose Human leukocyte interferon
Trial: 27419258
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined oral contraceptives (COCs)
Trial: 24464122
Drug: Vibration anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration anesthesia with dermal filler injections
Trial: 24464122
Drug: Dermal filler
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal filler injections alone (Control)
Trial: 17589893
Drug: Octreotide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.5 mg s.c. every 8 h for 6 weeks, followed by octreotide LAR 20 mg i.m. at week 4-8, and octreotide LAR 30 mg i.m. every 4 weeks thereafter)
Trial: 16243985
Drug: IA with
RxNorm normalized name: nutritional therapy for tyrosinemia with iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA with bupivacaine (0.25%) and clonidine (1 microg/kg) and morphine (5 mg)
Trial: 9657539
Drug: Fosinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (20 mg o.d.)
Trial: 8075734
Drug: Vaccine information
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine information pamphlets
Trial: 2673323
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo spray with vacuum cleaning
Trial: 2673323
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo spray without vacuum cleaning
Trial: 4619836
Drug: Diazepam in
RxNorm normalized name: diazePAM Intensol
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam in addition to standard treatment
Trial: 25138736
Drug: H. persicum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. persicum hydroalcoholic fruit extract (300 mg/day)
Trial: 21719012
Drug: Low-dose epidural
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose epidural analgesia (LEA)
Trial: 16847150
Drug: Early intensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intensive simvastatin therapy
Trial: 12878372
Drug: Eprosartan (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (600 mg/d for 1 week)
Trial: 9499493
Drug: Conventional pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pretreatment (heparin 15,000 I.E. and aspirin 500 mg i.v.)
Trial: 9710890
Drug: Interleukin-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interleukin-1 receptor antagonist (IL-1ra)
Trial: 31491796
Drug: Aminocaproic acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminocaproic acid (2,000 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Trial: 31491796
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1,300 mg per dose, three doses: 2 hours before surgery, 6 and 12 hours after surgery)
Trial: 31585740
Drug: Oleuropein-enriched chocolate
RxNorm normalized name: oleuropein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleuropein-enriched chocolate (40 g)
Trial: 31585740
Drug: Control chocolate
RxNorm normalized name: CHOCOLATE
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control chocolate spread (40 g)
Trial: 28455172
Drug: One IPV
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IPV dose at 14 weeks (SP‐1, GSK‐1, BBio‐1)
Trial: 28455172
Drug: Two IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two IPV doses at 14 and 36 weeks (SP‐2, GSK‐2, BBio‐2)
Trial: 28455172
Drug: One IPV
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IPV dose
Trial: 28455172
Drug: Two IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two IPV doses
Trial: 23183529
Drug: BOC/RGT (boceprevir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOC/RGT (boceprevir plus peginterferon-ribavirin using response guided therapy)
Trial: 21803011
Drug: Dronabinol 2.5
RxNorm normalized name: dronabinol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol 2.5 mg
Trial: 21803011
Drug: Dronabinol 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol 5.0 mg
Trial: 19398460
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus administration of meropenem (1 g 8 hourly)
Trial: 19398460
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of meropenem (1 g)
Trial: 19398460
Drug: All dosing
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosing regimens (intermittent bolus, extended, continuous infusion)
Trial: 19398460
Drug: Extended or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended or continuous infusion of meropenem
Trial: 15496218
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl 5 mg (oral) once daily from days 6 to 29
Trial: 11669506
Drug: Conventional AChE
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional AChE inhibitors (rivastigmine and donepezil)
Trial: 3543239
Drug: Cyclophosphamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (500 mg/m2 day 1), imidazole carboxamide (250 mg/m2 days 1 through 5), and doxorubicin (50 mg/m2 day 1)
Trial: 3543239
Drug: Cyclophosphamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2)
Trial: 27619827
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg long‐acting octreotide once every 4 weeks for 52 weeks, in addition to standard care
Trial: 27619827
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg long‐acting octreotide
Trial: 18756741
Drug: Therapy leading
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy leading to a decrease in NT-pro BNP levels
Trial: 18756741
Drug: Therapy leading
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy leading to a decrease in TNF-alpha levels
Trial: 18756741
Drug: Therapy leading
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy leading to a decrease in IL-6 levels
Trial: 10796063
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg enteric-coated aspirin
Trial: 1404679
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin
Trial: 8729092
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of n-3 polyunsaturated fatty acids (PUFA) from fish oils
Trial: 3956107
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose AVP (0.0125 m‐unit min‐1 kg‐1)
Trial: 3956107
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose AVP (0.3 m‐unit min‐1 kg‐1)
Trial: 30171161
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg [14C]finerenone (single oral administration)
Trial: 24248184
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg (1000 IU) vitamin D3
Trial: 24248184
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg (400 IU) vitamin D3
Trial: 21090563
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg every 3 weeks for four doses)
Trial: 21090563
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral budesonide (9 mg/d with gradual taper through week 16)
Trial: 16291162
Drug: Alimemazine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alimemazine (0.25 mg/kg 3 times a day, maximum 2.5 mg per dose)
Trial: 10224206
Drug: d4T monotherapy
RxNorm normalized name: STAVUDINE (d4T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d4T monotherapy (arm 1)
Trial: 8722345
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CY) administered as a 2-h infusion (60 mg/kg) for 2 days with MESNA as intermittent bolus infusion (20% of CY dose) every 6 h
Trial: 8722345
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CY) administered by continuous infusion (1500 mg/m2/day) for 4 days with MESNA administered concomitantly at an equivalent dose to CY by continuous infusion
Trial: 1853147
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) at a dose of 15 mg/kg/day
Trial: 1853147
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 15 mg/kg/day
Trial: 1853147
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CDCA and UDCA (7.5 + 7.5 mg/kg/day)
Trial: 6430666
Drug: 2.6 mg
RxNorm normalized name: menthol 2.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 mg nitroglycerin
Trial: 6430666
Drug: 6.5 mg
RxNorm normalized name: menthol 6.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg nitroglycerin
Trial: 6430666
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nitroglycerin
Trial: 6430666
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nitroglycerin
Trial: 6430666
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nitroglycerin (6 hours later)
Trial: 28918212
Drug: Miglitol (α-glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (α-glucosidase inhibitor)
Trial: 22093142
Drug: Intensive multifactorial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multifactorial treatment (IT) including lifestyle advice and strict regulation of metabolic parameters